MedTrace Logo

12-Week Trial Investigating L-carnitine Tartrate, Dihydrocapsiate and Protein Yeast Hydrolysate on Energy Intake and Expenditure in Overweight Adults

NCT06689501 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2025-07-11

No results posted yet for this study

Summary

This is a single-centre, double-blind, randomised, placebo-controlled, 2-arm, parallel-design trial.

This trial will examine the impact of a combined treatment of L-carnitine tartrate, dihydrocapsiate and protein yeast hydrolysate (otherwise known as the "study product") over 12 weeks on energy intake and expenditure in overweight and obese adults.

Approximately 44 participants will be recruited to this trial. Participants will give consent to investigator sites to collect their data. The participants will either be randomised to take the study product or placebo.

The main question that this trial aims to answer is:

The effect of the study product (L-carnitine tartrate, dihydrocapsiate and protein yeast hydrolysate) as compared to placebo on mean energy intake via 3 x 24h dietary recalls online at week 4.

Conditions

  • Overweight and Obesity

Interventions

COMBINATION_PRODUCT

SPICE BLEND CAPSULE

The study product is a powder mix of L-carnitine tartrate yeast protein hydrolysate and dihydrocapsiate.in the format of hard vegetable green capsules. Participants will consume a total of 4 capsules a day split in two servings.

OTHER

Placebo

The matching placebo is microcrystalline cellulose in the format of hard vegetable green capsules. Participants will consume a total of 4 capsules a day split in two servings.

Sponsors & Collaborators

  • Imperial College London

    collaborator OTHER

  • Imperial Clinical Trials Unit (ICTU)

    collaborator UNKNOWN

  • Société des Produits Nestlé (SPN)

    lead INDUSTRY

Principal Investigators

  • Edward Chambers · Imperial College London, Department of Metabolism, Digestion and Reproduction

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-30
Primary Completion
2025-06-26
Completion
2025-06-26

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06689501 on ClinicalTrials.gov